Holen Sie sich die Stockscreener-App
25.14
4.93%
-1.305
Handel nachbörslich:
24.75
-0.39
-1.55%
Septerna Inc Aktie (SEPN) Neueste Nachrichten
What is HC Wainwright's Forecast for Septerna Q1 Earnings? - MarketBeat
Analysts Conflicted on These Technology Names: Fortinet (FTNT), Septerna, Inc. (SEPN) and Oracle (ORCL) - The Globe and Mail
Septerna (SEPN) Q4 Loss Despite Revenue Surge Reinforces Bearish Profitability Narrative - simplywall.st
Truist Lifts Price Target on Septerna to $35 From $34, Keeps Buy Rating - marketscreener.com
Cantor Fitzgerald Maintains Overweight on Septerna, Inc. (SEPN) March 2026 - Meyka
Truist raises Septerna stock price target to $35 on trial progress - Investing.com
Cantor Fitzgerald reiterates Septerna stock rating on platform value - Investing.com
Septerna (SEPN) Reports Narrower Q4 Loss of $0.24/Share as Revenue Climbs to $24.1M - AlphaStreet
Septerna beats fourth quarter loss estimates on collaboration revenue - Investing.com
Decoding Septerna Inc (SEPN): A Strategic SWOT Insight - GuruFocus
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates - Bitget
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Earnings Flash (SEPN) Septerna Posts Q4 Loss $-0.24, vs. FactSet Est of Loss of $-0.24 - marketscreener.com
Biotech firm Septerna beats Q4 revenue expectations, net loss narrows - TradingView
Earnings Summary: Septerna Q4 - Benzinga
Earnings Flash (SEPN) Septerna, Inc. Reports Q4 Revenue $24.1M, vs. FactSet Est of $18.2M - marketscreener.com
How Investors May Respond To Septerna (SEPN) Advancing SEP-631 Into Phase 2b Urticaria Trials - simplywall.st
Can Septerna Inc. stock hit record highs againEarnings Performance Report & Fast Exit Strategy with Risk Control - Naître et grandir
Insider Selling: Septerna (NASDAQ:SEPN) Insider Sells 70,453 Shares of Stock - MarketBeat
Wells Fargo Sticks to Its Buy Rating for Septerna, Inc. (SEPN) - The Globe and Mail
SEPN: SEP-631 advances to phase II in CSU after robust phase I results; SEP-479 enters clinical trials - TradingView
SEPN: SEP-631 and SEP-479 advance with strong data, phase 2 and 1 trials planned, and pipeline growth - TradingView
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN), Payoneer (PAYO) and Porch Group (PRCH) - The Globe and Mail
A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment - Sahm
Septerna (SEPN) Receives Overweight Rating and Target Price Hike by Wells Fargo | SEPN Stock News - GuruFocus
Wells Fargo & Company Increases Septerna (NASDAQ:SEPN) Price Target to $48.00 - MarketBeat
Does SEP-631’s Phase 1 Proof-of-Mechanism and 2026 Trial Plan Reshape Septerna’s Mast Cell Strategy (SEPN)? - Yahoo Finance
[144] Septerna, Inc. SEC Filing - Stock Titan
Septerna (NASDAQ:SEPN) Price Target Raised to $40.00 at HC Wainwright - MarketBeat
Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Septerna Advances SEP-631 After Positive Phase 1 Results - TipRanks
SEPN: SEP-631 showed strong Phase 1 efficacy and safety, advancing to Phase 2 for urticaria in 2026 - TradingView
Septerna reports positive Phase 1 SEP-631 data; plans Phase 2b CSU study in 2H 2026 - TradingView
Positive SEP-631 trial data drives Phase 2 plan at Septerna (NASDAQ: SEPN) - Stock Titan
Septerna’s SEP-631 shows positive Phase 1 trial results - Investing.com Australia
Septerna’s SEP-631 shows positive Phase 1 trial results By Investing.com - Investing.com South Africa
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy - Bitget
Septerna says SEP-631 well-tolerated with adverse event profile comparable to placebo - marketscreener.com
Septerna Says SEP-631 Well-Tolerated With Adverse Event Profile Comparable To Placebo - TradingView
Septerna pill blocked induced skin wheals at low doses in Phase 1 test - Stock Titan
Sentiment Watch: Is Septerna Inc part of any ETFBear Alert & Free Community Consensus Stock Picks - baoquankhu1.vn
Why Septerna (SEPN) Is Up 6.4% After Surging GPCR Pipeline-Driven Revenue GrowthAnd What's Next - simplywall.st
Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Septerna, Inc. (SEPN) Stock Analysis: Unleashing a 12,113% Revenue Growth Amidst Biotech Innovations - DirectorsTalk Interviews
Zacks Research Upgrades Septerna (NASDAQ:SEPN) to Hold - MarketBeat
Aug Breakouts: Does Septerna Inc have a sustainable dividendMarket Trend Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Septerna stock reaches all-time high at 31.39 USD By Investing.com - Investing.com Australia
Septerna (NASDAQ:SEPN) Reaches New 12-Month HighStill a Buy? - MarketBeat
SEP-631 Phase 1 Readout: The Catalyst Set To Drive Septerna In 2026 (NASDAQ:SEPN) - Seeking Alpha
Septerna stock reaches all-time high at 31.39 USD - Investing.com
Will Septerna Inc outperform the market in YEAR2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Septerna to Present at TD Cowen 46th Annual Health Care Conference - Bitget
Biotech Septerna to webcast TD Cowen health talk on March 3 - Stock Titan
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):